Join Growin Stock Community!

禾生技4194.TW Overview

TW StockBiotech. & Medical
(No presentation for 4194)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

禾生技（4194）Overall Performance

禾生技（4194）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

禾生技（4194） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

禾生技（4194）Key Information

禾生技（4194）Profile

Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. It offers injectable devices for osteoarthritis and soft tissue injuries. The company also provides hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Holy Stone Healthcare was founded on January 18, 2001 and is headquartered in Taipei, Taiwan.

禾生技（4194）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

default symbol

4194

禾生技

7.00D

-3.43%

(-0.03)

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.79
PB Ratio
4.08
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
36.64%
Net Margin
-140.66%
Revenue Growth (YoY)
-40.46%
Profit Growth (YoY)
-49.70%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.79
PB Ratio
4.08
Price-to-FCF
-
Gross Margin
36.64%
Net Margin
-140.66%
Revenue Growth (YoY)
-40.46%
Profit Growth (YoY)
-49.70%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is 4194's latest earnings report released?

    The most recent financial report for 禾生技 (4194) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4194's short-term business performance and financial health. For the latest updates on 4194's earnings releases, visit this page regularly.

  • How is 4194's revenue growth?

    In the latest financial report, 禾生技 (4194) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4194 have?

    At the end of the period, 禾生技 (4194) held Total Cash and Cash Equivalents of 206.54M, accounting for 0.71 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 4194's EPS continuing to grow?

    According to the past four quarterly reports, 禾生技 (4194)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.29. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4194?

    禾生技 (4194)'s Free Cash Flow (FCF) for the period is 3.79M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100.98% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.